-
Something wrong with this record ?
Formulation Development, Physicochemical Characterization and In Vitro-In Vivo Drug Release of Vaginal Films
K. Ghosal, BT. Hazra, BB. Bhowmik, S. Thomas,
Language English Country Netherlands
Document type Journal Article
- MeSH
- Administration, Intravaginal MeSH
- Chemical Phenomena MeSH
- Dideoxynucleosides administration & dosage pharmacokinetics MeSH
- Rabbits MeSH
- Anti-HIV Agents administration & dosage pharmacokinetics MeSH
- Dosage Forms * MeSH
- Drug Carriers administration & dosage chemistry MeSH
- Drug Compounding * MeSH
- Drug Liberation * MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
PURPOSE: The purpose of this study was formulation and optimization of vaginal film formulation containing abacavir (ABC), a potent nucleoside reverse transcriptase inhibitor. METHODS: Vaginal films were prepared by solvent evaporation method using hydroxypropyl methylcellulose (HPMC) blended with polyvinyl pyrrolidone (PVP). Various physicochemical parameters of the prepared films such as drug content, thickness, tensile strength, percentage elongation at break, drug polymer interaction, swelling capacity, folding endurance, bio-adhesion, pH, and moisture content were evaluated with morphological studies. In vitro release study and in vivo release study were also performed. RESULTS: Films exhibited favorable physicochemical properties. The in vitro study showed that HPMC-PVP combination can control the release of abacavir through vaginal films with higher amount of PVP in the formulation resulting in an enhanced drug release rate. During the in vivo study in rabbits, systemic absorption of the drug was noted and the films remained intact for long in vagina without causing any sort of irritations. CONCLUSION: Thus, in a nutshell, the findings of our experimental work indicate that such films can be considered as a novel drug carrier system for the treatment of AIDS and other sexually transmitted diseases (STDs), and are suitable for local as well as systemic effects.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031884
- 003
- CZ-PrNML
- 005
- 20171101102640.0
- 007
- ta
- 008
- 171025s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1570162x14666151113123040 $2 doi
- 035 __
- $a (PubMed)26564015
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Ghosal, Kajal $u Flat No: 26, 10 Vychodilova, Zaboversky 2551, Brno 61600, Czech Republic. kaju_3_ju@rediffmail.com.
- 245 10
- $a Formulation Development, Physicochemical Characterization and In Vitro-In Vivo Drug Release of Vaginal Films / $c K. Ghosal, BT. Hazra, BB. Bhowmik, S. Thomas,
- 520 9_
- $a PURPOSE: The purpose of this study was formulation and optimization of vaginal film formulation containing abacavir (ABC), a potent nucleoside reverse transcriptase inhibitor. METHODS: Vaginal films were prepared by solvent evaporation method using hydroxypropyl methylcellulose (HPMC) blended with polyvinyl pyrrolidone (PVP). Various physicochemical parameters of the prepared films such as drug content, thickness, tensile strength, percentage elongation at break, drug polymer interaction, swelling capacity, folding endurance, bio-adhesion, pH, and moisture content were evaluated with morphological studies. In vitro release study and in vivo release study were also performed. RESULTS: Films exhibited favorable physicochemical properties. The in vitro study showed that HPMC-PVP combination can control the release of abacavir through vaginal films with higher amount of PVP in the formulation resulting in an enhanced drug release rate. During the in vivo study in rabbits, systemic absorption of the drug was noted and the films remained intact for long in vagina without causing any sort of irritations. CONCLUSION: Thus, in a nutshell, the findings of our experimental work indicate that such films can be considered as a novel drug carrier system for the treatment of AIDS and other sexually transmitted diseases (STDs), and are suitable for local as well as systemic effects.
- 650 _2
- $a aplikace intravaginální $7 D000282
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a látky proti HIV $x aplikace a dávkování $x farmakokinetika $7 D019380
- 650 _2
- $a chemické jevy $7 D055598
- 650 _2
- $a dideoxynukleosidy $x aplikace a dávkování $x farmakokinetika $7 D015224
- 650 12
- $a lékové formy $7 D004304
- 650 _2
- $a nosiče léků $x aplikace a dávkování $x chemie $7 D004337
- 650 12
- $a příprava léků $7 D004339
- 650 12
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a králíci $7 D011817
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hazra, Bipad Taran
- 700 1_
- $a Bhowmik, Benoy Brata
- 700 1_
- $a Thomas, Sabu
- 773 0_
- $w MED00007898 $t Current HIV research $x 1873-4251 $g Roč. 14, č. 4 (2016), s. 295-306
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26564015 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171101102732 $b ABA008
- 999 __
- $a ok $b bmc $g 1255477 $s 992911
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 14 $c 4 $d 295-306 $i 1873-4251 $m Current HIV research $n Curr HIV Res $x MED00007898
- LZP __
- $a Pubmed-20171025